Company intelligence / Profile preview

Huxley Health

London, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Huxley is a clinical-stage biotechnology company specializing in immuno-psychiatry, focusing on the intersection of the immune system and mental health. The company is developing novel therapies for central nervous system disorders, with a primary focus on treatment-resistant depression (TRD). Its lead program, HUX-1, is a small molecule targeting the P2X7 receptor to modulate neuroinflammation, a key driver in psychiatric conditions. Founded by leading researchers from King's College London, Huxley aims to provide precision medicine approaches to patients who do not respond to traditional antidepressants. The company is headquartered in London and is backed by venture capital firms such as Hoxton Ventures.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Huxley Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huxley Health.

Explore the full profile